You have that right, DDbuyer just ripped apart ever point that Martin has tried to establish to tear down NEOP.
Here is the recent thread and guess what? No reply or rebuttals from Marty!!!
Nice job DDBuyer providing a proper and supported rebuttal to this trash talk on NEOP
Well worth the read to all NEOP-ers.
The recent Thread rebuttal (dated 06/09/11) from DDBuyer to Martin Shreli:
(15 comments)Send Message" I commissioned a survey of hospitals to determine their acquisition price for Tc-99 sulfur colloid and the results confirmed my prior writing on the topic." - Martin Shkreli
Well then you should share that survey and let's compare it to the information prepared and provided to Neoprobe by Cardinal Health, the nations largest radiopharmaceutical distributor... the very same distributor that is establishing the retail price for Lymphoseek based on their CURRENT prices.
DDbuyer 9 Jun, 11:18 AM
(15 comments)Send Message"Summer Street conducted a poll of physicians at ASCO and mentioned the physicians felt Lymphoseek would not receive approval" - Martin Shkreli
Absolutely False. I just reread the Summer Street report from yesterday, and it made no mention that "physicians felt Lymphoseek would not receive approval".
DDbuyer
9 Jun, 11:37 AM
(15 comments)Send Message“There were 22 Serious Adverse Events (SAEs) in NEO03-09 which were not well-disclosed by the company.” – Martin Shkreli
To the contrary, they were explicitly described in detail at ASCO detailing each and every event, along with the investigators conclusions. The investigators concluded that the adverse events were either minor in nature (rashes, nausea, etc.) or, for the more significant events, consistent with historically documented side effects of Isosulfan Blue, including anaphylaxis.
The investigators are well aware of the history of Isosulfan Blue, and are in a much better position than a hedge fund manager to determine cause and effect of an adverse event during a clinical trial.
You were not involved, Martin. The investigators were, and they were in the position to assess the correlation between the earlier injection of Lymphoseek and the later injection of Isosulfan Blue, and then make the proper decision regarding the association of an adverse event with each respective agent.
You may wish to note that the FDA requires a warning label on Isosulfan Blue noting the history of an overall incidence of hypersensitivity reactions in approximately 2% of patients including life- threatening anaphylactic reactions, respiratory distress, shock, angioedema, urticaria, and pruritus. In laboratory Tests Lymphazurin (isosulfan blue) 1% interferes with measurements of oxygen saturation by pulse oximetry and of methemoglobin by gas analyzer4. Additionally, Isosulfan Blue can result in transient or long-term (tattooing) blue coloration.
The adoption of Lymphoseek will alleviate, and in all likelihood eliminate, this problem incurred by the use of VBD.
You see, Lymphoseek has been tested on 508 patients to date in Phase 1, 2 and 3 FDA clinical trials over a period of 10+ years (starting in 2001). This is in addition to a portion of the estimated 196 additional patients currently undergoing the Head & Neck Sentinel Trial who have completed their surgeries, also with no significant adverse events to date.
During all of the Lymphoseek trials and subsequent follow ups during this 10+ year period, not one (yes ZERO) significant adverse event has ever been attributed to Lymphoseek. This is an enviable, and practically unheard of, safety record for a new compound.
The same cannot be said for Isosulfan Blue, or even Sulphur Colloid for that matter.
DDbuyer
9 Jun, 11:47 AM
(15 comments)Send Message"...they're recycling proceeds into Lymphoseek development..." - Martin Shkreli
Again, you're uninformed Martin. The company has stated numerous times on conference calls that Lymphoseek is fully funded through FDA completion and they need no additional capital for that program.
Capital raised through the sale of their Gamma Device product line will be used to expand their drug pipeline, through either acquisition or in-licensing of additional products. Some speculate that those funds may also be used to complete the RIGS program, but the company has not confirmed this.
DDbuyer
9 Jun, 11:55 AM1
(15 comments)Send Message"Good luck with your complaints!" - Martin Shkreli
If the complaint goes nowhere, so be it. But if it does, you'll hear about it from another direction. We'll let others decide that outcome. No need to debate it here...
DDbuyer
9 Jun, 11:59 AM1
(15 comments)Send MessageWhere are you Marty...?
You pop in occasionally, post an evasive blurb that ducks the issues then you hide again. I'm running circles around you, and this is supposed to be your venue.
It's noon. Go get lunch. But when you come back bring your A-game. This is getting boring...
DDbuyer
More to come......... I'm sure!!
Kels
Market Data 
Markets 
AI
